Eli Lilly and rival drugmaker Novo Nordisk are the leading companies in the GLP-1 space, but others are emerging. Among them is Pfizer; in September that company announced it would acquire Metsera, a ...
The lowest doses of Eli Lilly’s Zepbound and Novo Nordisk's Wegovy could be available for as little as $149 a month.
The White House is close to announcing a deal with drugmakers Eli Lilly and Novo Nordisk that would cut the price of obesity drugs to $149 per month in some cases and extend coverage to certain ...
Obesity drugs have become an increasingly popular method of weight loss but most are not covered by insurance for that ...
A deal with Lilly and Novo would be significant for the administration’s push for lower drug prices for Americans.
Eli Lilly and Company (NYSE:LLY) shares are trading slightly lower on Tuesday after its previous gains following reports ...
Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock are in focus as the companies are nearing to strike U.S. pricing deals for ...
Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A ...
Such conversations are becoming increasingly common as demand for weight-loss drugs explodes in urban India - a country with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback